Clinical pharmacology of buprenorphine

$0P50FY2002DANIH

University Of Michigan At Ann Arbor, Ann Arbor MI

Investigators

Linked publications & trials

Paper 29413433 Paper 28584876 Paper 26595426 Paper 25765913 Paper 25630964 Paper 23043264 Paper 22840814 Paper 22216959 Paper 21055630 Paper 20686752 Paper 19842669 Paper 19303919 Paper 19253983 Paper 18515643 Paper 18510792 Paper 18499626 Paper 18422019 Paper 18397572 Paper 18325678 Paper 17988766 Paper 17986650 Paper 17962026 Paper 17924783 Paper 17887741 Paper 17763108 Paper 17721251 Paper 17601558 Paper 17351424 Paper 17220427 Paper 17114567 Paper 17004724 Paper 17002226 Paper 16950210 Paper 16913723 Paper 16809477 Paper 16766718 Paper 16571623 Paper 16537798 Paper 16443205 Paper 16364263 Paper 16291875 Paper 16286814 Paper 16262189 Paper 16258020 Paper 16220339 Paper 16163520 Paper 15733546 Paper 15680187 Paper 15571439 Paper 15363957 Paper 15322724 Paper 15193177 Paper 15114434 Paper 15100607 Paper 15018359 Paper 14997174 Paper 14724040 Paper 14722329 Paper 14647482 Paper 14640558 Paper 14609727 Paper 14557718 Paper 12915238 Paper 12902992 Paper 12825957 Paper 12676881 Paper 12672258 Paper 12573680 Paper 12519069 Paper 12467704 Paper 12457638 Paper 12446706 Paper 12396021 Paper 12388657 Paper 12373441 Paper 12373435 Paper 12373418 Paper 12019201 Paper 12019200 Paper 12007745 Paper 11961075 Paper 11919661 Paper 11812502 Paper 11797065 Paper 11786497 Paper 11784158 Paper 11752111 Paper 11679056 Paper 11679055 Paper 11518097 Paper 11504802 Paper 11408532 Paper 11407313 Paper 11329495 Paper 11295322 Paper 11294396 Paper 11181908 Paper 11150174 Paper 11082449 Paper 11082429

Abstract

DESCRIPTION: (provided by applicant) Buprenorphine is a long acting partial mu opioid agonist being developed as a maintenance treatment for opiod dependence. Buprenorphine attenuates the effects of challenge doses of opioids in humans, and this effect persists in a dose-related manner for periods up to 72 hours or longer. PET studies using [11C]carfentanyl (a high affinity, selective mu opiate receptor ligand) have found that buprenorhine produces dose related blockade of brain mu opioid receptors four hours after its administration. Pharmacokinetic studies have shown that buprenorphine administered sublingually reaches peak plasma levels in 90-120 minutes with a half-life of 12 hrs. The primary goal of this proposal is to compare the extent and time course of buprenorphine?s attenuation of the pharmacological effects of challenge doses of hydromorphone with its prevention of the binding of the mu opioid radiolabeled ligand, [11C]carfentanil, to brain mu receptors in opiate dependent participants. These effects will be examined at 4, 28, 52, and 76 hours after the last buprenorphine dose to determine if opioid blockade and mu opioid receptor binding decrease at comparable rates. Pharmacokinetic studies will also be conducted to determine the plasma levels of buprenorphine for comparison. We are hypothesizing that the magnitude of buprenorphine?s blockade of the pharmacological effects of hydromorphone is correlated with its leyel of mu opioid receptor binding. Secondly, we are hypothesizing that the rate of decline of the plasma levels of buprenorphine will be greater than the rate of decline of its binding to mu opioid receptors in the brain. This research will continue our exploration of the human pharmacology of buprenorphine as a prototypic opiate addiction treatment agent and serve to demonstrate the utility of pharmacodynamic, brain imaging and pharmacokinetic components of a multidimensional approach to the evaluation of new pharmacological treatment interventions.

View original record on NIH RePORTER →